The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Start Date05 Jan 2026

Sponsor / Collaborator

University Health Network

NCT06934655

/ Not yet recruitingPhase 3IIT

Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth

This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.

Start Date01 Nov 2025

Sponsor / Collaborator

Children's Hospital Los Angeles

NCT06909006

/ Not yet recruitingPhase 3IIT

Obesity and Semaglutide in Type 1 Diabetes Therapy: a Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial

The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.

Start Date01 Oct 2025

Sponsor / Collaborator

Zealand University Hospital

[+1]

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

491

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 May 2025·Diabetes Therapy

PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes

Article

Author: Deinega, Alisa ; Giordano, Carla ; Desenzani, Paolo ; Memoli, Pasqualina ; Faldetta, Maria Cassone ; Gioia, Daniela ; Ventura, Claudio ; Serra, Rosalia ; Gallo, Marco ; Berra, Cesare ; Braae, Uffe Christian ; Memoli, Giuseppe ; Manetti, Francesco ; Bisio, Alessandro ; Paccagnella, Agostino ; Strazzabosco, Marco ; Mirani, Marco ; Marangoni, Alberto ; Anzaldi, Massimiliano ; De Cata, Pasquale ; Girelli, Angela ; Di Loreto, Chiara ; De Cosmo, Salvatore ; Scatena, Alessia ; Manti, Roberta ; Ferrara, Lidia

INTRODUCTION:

The PIONEER REAL Italy study examined the clinical outcomes associated with oral semaglutide in real-world settings.

METHODS:

This was a multicenter, prospective, non-interventional, single-arm study in adults with type 2 diabetes (T2D) who were treatment-naive to injectable glucose-lowering medications. Participants initiated oral semaglutide at doses of 3, 7, or 14 mg, and were followed for 34-44 weeks. The primary endpoint was the change in glycated hemoglobin (HbA_1c) from baseline to the end of study (EoS). Secondary endpoints were the change in body weight (BW), the percentage of participants attaining HbA_1c < 7%, composite endpoints of HbA_1c reduction ≥ 1%-point plus BW reduction (≥ 3%/ ≥ 5%), and treatment satisfaction measured using Diabetes Treatment Satisfaction Questionnaires (DTSQ) status. Safety was assessed in participants who received ≥ 1 dose of oral semaglutide.

RESULTS:

Of 445 eligible participants, 398 completed the study; 351 (78.9%) remained on oral semaglutide at EoS. The median time of treatment follow-up was 40 weeks for each participant. At baseline, participants had a mean (standard deviation [SD]) age of 62.9 (10.2) years, HbA_1c of 7.8% (1.3), T2D duration of 8.0 (6.9) years, and BW of 87.8 (19.0) kg. The estimated changes (95% confidence interval) from baseline to EoS in HbA_1c and BW were - 0.9%-points (- 1.01 to - 0.82; p < 0.0001) and - 3.8 kg (- 4.45 to - 3.24; p < 0.0001), respectively. At EoS, 65.1% achieved HbA_1c < 7%; 25.5% and 19.1% reached HbA_1c reduction ≥ 1%-point plus ≥ 3% and ≥ 5% reduction in BW, respectively. DTSQ status improved significantly at EoS (estimated change + 5.24; 95% CI, 5.24 to 6.61, p < 0.0001). Of participants who remained on oral semaglutide at EoS, 72.6% received a 7-mg dose. No new safety signals were observed.

CONCLUSIONS:

In Italy, the real-world clinical outcomes associated with oral semaglutide in adults with T2D complemented the findings from clinical trials. This reassures oral semaglutide usage in routine clinical practice.

TRIAL REGISTRATION:

NCT05230615.

01 Apr 2025·Clinical Gastroenterology and Hepatology

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis

Review

Author: Samanta, Jayanta ; Dhar, Jahnvi ; Crinò, Stefano Francesco ; Dinis-Ribeiro, Mario ; Facciorusso, Antonio ; Hassan, Cesare ; Gkolfakis, Paraskevas ; Triantafyllou, Konstantinos ; Fuccio, Lorenzo ; Maida, Marcello ; Boskoski, Ivo ; Ramai, Daryl ; Chandan, Saurabh ; Arvanitakis, Marianna ; Anderloni, Andrea

BACKGROUND AND AIMS:

Limited evidence exists regarding the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on upper endoscopy. Therefore, a meta-analysis was conducted to comprehensively review the available evidence on this subject.

METHODS:

A systematic bibliographic search was carried out until May 2024. Pooled estimates were analyzed using a random-effects model, with results presented as odds ratio (OR) and 95% confidence interval (CI). The primary outcome assessed was the rate of retained gastric content (RGC), while secondary outcomes included rates of aborted and repeated procedures, adverse event rate, and rates of aspiration.

RESULTS:

This analysis included 13 studies involving a total of 84,065 patients. Patients receiving GLP-1RA therapy exhibited significantly higher rates of RGC (OR, 5.56; 95% CI, 3.35 to 9.23), a trend that was consistent among patients with diabetes (OR, 2.60; 95% CI, 2.23 to 3.02). Adjusted analysis, accounting for variables such as sex, age, body mass index, diabetes, and other therapies, confirmed the elevated rates of RGC in the GLP-1RA user group (adjusted OR, 4.20; 95% CI, 3.42 to 5.15). Furthermore, rates of aborted and repeated procedures were higher in the GLP-1RA user group (OR, 5.13; 95% CI, 3.01 to 8.75; and OR, 2.19; 95% CI, 1.43 to 3.35; respectively). However, no significant differences were found in AE and aspiration rates between the 2 groups (OR, 4.04; 95% CI, 0.63 to 26.03; and OR, 1.75; 95% CI, 0.64 to 4.77; respectively).

CONCLUSION:

Use of GLP-1RAs is associated with increased retention of gastric contents and more frequent aborted procedures during upper endoscopy. However, the adverse event and aspiration rates do not seem different; therefore, adjusting fasting time instead of routinely withholding GLP-1RAs could be reasonable in these patients.

01 Apr 2025·DIABETOLOGIA

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial

Article

Author: Chen, Liming ; Benamar, Malik ; Fu, Ariel ; Yabe, Daisuke ; Zueger, Thomas ; Réa, Rosângela ; Riveline, Jean-Pierre ; Nishida, Tomoyuki ; Jódar, Esteban ; Lingvay, Ildiko

Abstract:

Aims/hypothesis:

COMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 analogue) 1.0 mg in individuals with type 2 diabetes inadequately managed with GLP-1 receptor agonist (GLP-1 RA) therapy, with or without additional oral glucose-lowering medications.

Methods:

This 52 week, randomised, multicentre, open-label, parallel group, Phase IIIa trial was conducted across 121 sites in 13 countries/regions. Adults with type 2 diabetes (HbA1c 53.0–85.8 mmol/mol [7.0–10.0%]) receiving GLP-1 RA therapy with or without additional oral glucose-lowering medications were randomly assigned 1:1 to once-weekly IcoSema or once-weekly semaglutide 1.0 mg. The primary endpoint was change in HbA1c from baseline to week 52; superiority of IcoSema to semaglutide 1.0 mg was assessed. Secondary endpoints included change in fasting plasma glucose and body weight (baseline to week 52), and combined clinically significant (level 2; <3.0 mmol/l) or severe (level 3; associated with severe cognitive impairment requiring external assistance for recovery) hypoglycaemia (baseline to week 57).

Results:

Overall, 683 participants were randomised using a Randomisation and Trial Supply Management system to IcoSema (n=342) or semaglutide 1.0 mg (n=341). Mean ± SD baseline characteristics were as follows: HbA1c 64.0±8.2 mmol/mol (8.0±0.7%); diabetes duration 12.6±6.9 years; and BMI 31.1±4.7 kg/m2. From baseline to week 52, mean change in HbA1c was −14.7 mmol/mol (−1.35%-points) in the IcoSema group and −9.88 mmol/mol (−0.90%-points) in the semaglutide group; the estimated treatment difference (ETD) was –4.85 (95% CI −6.13, −3.57) mmol/mol (−0.44 [95% CI −0.56, −0.33]%-points), confirming superiority of IcoSema to semaglutide (p<0.0001). The estimated mean change in fasting plasma glucose from baseline to week 52 was statistically significantly reduced with IcoSema vs semaglutide (−2.48 mmol/l vs −1.43 mmol/l, respectively; ETD −1.05 [95% CI −1.36, −0.75] mmol; p<0.0001). Mean change in body weight from baseline to week 52 was statistically significantly different between groups: +0.84 kg for IcoSema vs −3.70 kg for semaglutide (ETD 4.54 kg [95% CI 3.84, 5.23]; p<0.0001). There was no statistically significant difference in the rate of combined clinically significant or severe hypoglycaemia between IcoSema and semaglutide (0.042 vs 0.036 episodes per person-year of exposure; estimated rate ratio 1.20 [95% CI 0.53, 2.69]; p=0.66). The proportion of participants experiencing gastrointestinal adverse events was similar between treatment groups (IcoSema 31.4%; semaglutide 34.4%).

Conclusions/interpretation:

In people living with type 2 diabetes inadequately managed with GLP-1 RA therapy, with or without additional oral glucose-lowering medications, switching to once-weekly IcoSema in comparison with once-weekly semaglutide 1.0 mg demonstrated superiority in HbA1c reduction, similar rates of clinically significant or severe hypoglycaemia, and similar frequency of gastrointestinal adverse events. However, weight change from baseline to week 52 was statistically significantly in favour of semaglutide 1.0 mg.

Trial registration:

ClinicalTrials.gov NCT05259033

Funding:

This trial was funded by Novo Nordisk

Graphical Abstract:

2,001

News (Medical) associated with Semaglutide (Novo Nordisk)

22 Apr 2025

·www.echemi.com

Novo Nordisk to Phase Out ₹800 Cr Insulin Brand in India Within 6 Months

In a significant shift, Novo Nordisk is set to discontinue its top-selling insulin product, Human Mixtard, in India. This decision aligns with the company’s global strategy to prioritize newer, patented diabetes and weight-loss therapies like Ozempic and Wegovy, which offer higher profitability . Human Mixtard, a ₹800 crore brand, along with other older insulin products such as Actrapid, Insulatard, Insulin Detemir, Levemir, and Xultophy, will be phased out over the next six months. These products are primarily available in pre-filled disposable pens and cartridges. Novo Nordisk has informed its marketing partner, Abbott India, that these products will be discontinued once current stocks are depleted . While vial forms of Human Mixtard, Actrapid, and Insulatard will remain available, the transition away from pen devices may pose challenges for patients who prefer the convenience and accuracy of pens over traditional syringes. This move could significantly impact India’s ₹5,000 crore insulin market, especially as Novo Nordisk prepares to introduce its newer therapies in the country .

Drug Approval

17 Apr 2025

·www.fiercepharma.com

Eli Lilly is overtaking Novo Nordisk in the diabetes, obesity market: BMO analysts

In calling Eli Lilly the "tortoise" and Novo Nordisk the "hare," BMO Capital Markets says that Lilly is surpassing its rival in the diabetes and obesity market. The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company compared to those of its Danish rival.In pronouncing the change of the guard, BMO has downgraded Novo’s shares from “outperform” to “market perform.” Translation: The analysts are advising investors to hold Novo shares rather than buying more of them.The report comes as Lilly and Novo remain the two fastest-growing large pharmaceutical companies, based largely on booming sales of their diabetes and obesity products. With their surges over the last few years, Lilly and Novo have become the drugmakers with the largest market caps in the U.S. and Europe, respectively, with Lilly’s value nearly twice that of second-place Johnson & Johnson.While the momentum for Lilly is accelerating, that for Novo is slowing. In 2024, Lilly and Novo grew by 32% and 26%, respectively. This year, the gulf between their growth is expected to widen, with Lilly projecting another 32% increase in revenue at the midpoint of its estimate, compared to Novo guiding for growth of between 16% and 24%. “Our market perform thesis asserts that Novo Nordisk shares will remain less competitive vs. other peers in the cardiometabolic market (namely Lilly),” BMO analyst Evan Seigerman wrote in a report to investors. “We expect Lilly’s Mounjaro and Zepbound to continue to take incremental U.S. share from Novo’s Ozempic and Wegovy.”Seigerman also points out that among the companies, Lilly has the most promising cardiometabolic candidate in its clinical portfolio in oral GLP-1 orforglipron. Today, Lilly posted data that live up to the company’s pledge that it could create an oral drug with “efficacy, safety and a tolerability profile that is similar to that of an injectable single-acting GLP-1,” Dan Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer, said during the company’s most recent quarterly conference call.With the Lilly trial result and BMO report, Novo’s shares dropped by 8% on Thursday to $58.08. Conversely, Lilly's stock price jumped about 14.5% to $840. “While Novo had the headstart with approval of semaglutide, we believe that this first mover advantage has waned, with Lilly's tirezepatide taking share rapidly,” BMO's analysts wrote. “We see this trend only accelerating with orforglipron and retatrutide.”Semaglutide is the generic name for Novo's GLP-1 products Ozempic and Wegovy. Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively.In addition, retatrutide is Lilly’s next-generation weight loss candidate. In a phase 2 trial, the injected drug triggered a median weight loss of 24%. Another factor in the market clash is reliable supply. Even though the FDA has removed Novo's semaglutide from its shortage list, the BMO analysts said the company's supply issues "continue to linger." “We think that physicians may have permanently shifted preference to tirezepatide, given challenges accessing product. While compounding is set to end, we do not see this as a major inflection for semaglutide sales,” the analysts added.Also contributing to physician preferences are recent head-to-head data, which have shown “clear superiority” of Lilly's tirzepatide over Novo's semaglutide, BMO said. The analysts also believe recent clinical results for Novo’s next-gen treatment CagriSema indicate it will have difficulty unseating Lilly's tirzepatide as the favored obesity drug on the market.

Clinical ResultPhase 2

17 Apr 2025

·www.prnewswire.com

Prominent Psychiatrist Introduces Breakthrough Treatment for Addiction

NEW YORK, April 17, 2025 /PRNewswire/ -- Dr. DiFrancesco () is deeply enthusiastic about new developments in the treatment of addiction and has launched a new website for individuals who would like to learn more and are seeking treatment. Experience the full interactive Multichannel News Release here: Continue Reading Dr. Eileen DiFrancesco Introduces Breakthrough Treatment For Addiction Dr. Eileen DiFrancesco Introduces Breakthrough Treatment For Addiction Dr. Eileen DiFrancesco a physician in New York City has specialized in Psychiatry and Psychopharmacology for over two decades treating a wide variety of neuropsychiatric disorders, focusing on addiction. She has had the opportunity to train in Ivy League schools and work in the ivory towers of Medicine, but unfortunately, she says there has never been an effective medication for the treatment of addiction - until now. Patients who are taking the popular drug Ozempic, also known as semaglutide which was developed for the treatment of diabetes and weight loss are experiencing remarkable results. Surprisingly, they are not only reporting a decrease in the over consumption of food, but also little or no interest in alcohol. DiFrancesco says this is not a coincidence or a side effect. As published in JAMA, Nature and Science Direct -these medications target neural circuits involved in reward and satiety and therefore greatly curb craving for addictive substances. Semaglutide and a similar medication tirzepatidetide are medication's that mimic a natural hormone called glucagon -like peptide – 1 or GLP -1. These hormones are activated when the GLP one receptor agonist attached to their receptors. What is truly exciting is that GLP one receptors are all over the brain reward pathway. This pathway exists to provide a sense of pleasure or reward when we do something that is essential for our survival or survival of the species such as eating healthy foods having sex and nurturing relationship relationships. The reward or sense of pleasure is intended to make us repeat these behaviors so that our species will survive because we eat well, procreate and take care of others. However, substances and things that are highly pleasurable can take over these reward circuits. This causes the natural rewards to become less pleasurable and even ignored. This is what addictive substances do, they hijack the reward pathway in such a way that they become the focus of an individual's life. According to JAMA, a nationwide register based study with GLP one receptor agonist Semaglutide were associated with a markedly, reduced risk of alcohol use disorders and substance use disorder related hospitalizations. In the journal nature, the administration of GLP one has convincingly shown to reduce alcohol intake and pre-clinical models. Observational studies clearly show that GLP one receptor Agnes are associated with non-volitional reduction and the use of alcohol, nicotine, cocaine and opioids. When GLP one receptor agonist activate the GLP one receptors in the reward pathway, the sense of reward from the addictive substances, including alcohol, nicotine cocaine, and even opioid becomes less rewarding. This serendipitous finding is truly amazing and wonderful. When combined with already existing treatment for addiction, DiFrancesco Psychiatry feels there is finally help and hope for treating this destructive and debilitating disease. If you or someone you love is suffering and would like to learn more, please contact us at: [email protected]. About Dr. Eileen DiFrancesco Dr. Eileen DiFrancesco graduated with honors from the University of Pennsylvania where she received her Bachelor's Degree. After earning a medical degree from Temple University School of Medicine, she received additional training in both Psychiatry and Neurology. Upon completing residency training at Mount Sinai Medical Center in New York City she was appointed Medical Director of the Learning Laboratory, a private facility in Connecticut. There she specialized in diagnosing and treating Attention Deficit Disorder, Addiction, Depression and Bipolar Disorder, using Quantitative EEG also known as Brain Mapping. Her diagnostic skills were also utilized at the Mount Sinai School of Medicine where she assessed psychotic adolescents for Schizophrenia treatment and eligibility for research protocols. SOURCE xsrxdoctor WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03574597 (SELECT, PRNewswire) Manual	Phase 3	Overweight \| Obesity	17,604	司美格鲁肽2.4mg	konhldazqs(ayusntrsjm) = kwtxuuuypb xsqlmfdatp (otvxebiafx ) View more	Positive	03 Apr 2025
				Placebo	-
NCT04998136 (CTgov)	Phase 3	Obesity	150	Placebo (semaglutide 2.4 mg)	ebnlsgubxy(gwojppifcr) = oqjxpgnjfg joxeelmcgs (tuambrhvwl, 5.8) View more	-	03 Apr 2025
NCT03914326 (SOUL, Pubmed \| N Engl J Med) Manual	Phase 3	Diabetes Mellitus, Type 2	9,650	Oral Semaglutide	hbbfozmcur(pzhzgmscwy) = hiuyegzniw bdgtthktgk (hadhsuliro ) View more	Positive	29 Mar 2025
				Placebo	hbbfozmcur(pzhzgmscwy) = hwfomcfpmn bdgtthktgk (hadhsuliro ) View more
NCT05230615 (PIONEER REAL Italy, Pubmed \| Diabetes Ther)	Not Applicable	Diabetes Mellitus, Type 2	445	Oral Semaglutide 3 mg	imgxlnerms(pckjsqmlpa) = mjjcxoikxu emhtnjhbpt (cobqcocrug )	Positive	25 Mar 2025
				Oral Semaglutide 7 mg	imgxlnerms(pckjsqmlpa) = kznctddzmo emhtnjhbpt (cobqcocrug )
NCT05520775 (CTgov)	Phase 2	Alcohol Use Disorder \| Smoking	48	Semaglutide (Semaglutide)	nwrdxulwza(qxyidwvetb) = vaxykvgdkd cxjyhpidjj (pezsofducf, 27.98) View more	-	25 Mar 2025
				Sham/placebo (Sham/Placebo)	nwrdxulwza(qxyidwvetb) = hwdzorvlfq cxjyhpidjj (pezsofducf, 24.49) View more
NCT03819153 (FLOW, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Chronic Kidney Diseases	3,533	semaglutide (Semaglutide)	mygkybghzx = jmmvdubmrx wucqixdvia (nbusxvnwdd, spifivisxr - bpdsvzccfd) View more	-	20 Mar 2025
				Placebo (semaglutide) (Placebo)	mygkybghzx = obofmhudmh wucqixdvia (nbusxvnwdd, avjckruzjw - cdkdgijlbj) View more
NCT04560998 (STRIDE, Pubmed \| Lancet) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	792	Semaglutide	uybeobwaxd(mbepkxiwqu) = iaxlfbaofw bzoyfkygob (asfvvobqca, 0.95 - 1.55) View more	Positive	01 Mar 2025
				Placebo	uybeobwaxd(mbepkxiwqu) = svblsecndr bzoyfkygob (asfvvobqca, 0.86 - 1.36) View more
NCT04216589 (SLIM LIVER Study, Pubmed \| Clin Infect Dis)	Phase 2	HIV Wasting Syndrome	-	Semaglutide	lfpzepqvgo(uasdatrzsz) = hgmhpzgmbq lmycqzfkxy (zwnxztzkgl, -2.7 to 0.10) View more	Positive	24 Feb 2025
NCT05533632 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	104	semaglutide	yllzowanat = jzkwkcjylr lnafhbbbxr (enlwwwwfmg, daghggymyc - wwurakvzyg) View more	-	10 Feb 2025
TRANSITION-T2D (Pubmed \| Diabetes Obes Metab)	Not Applicable	-	60	Semaglutide 1.0 mg plus insulin degludec	qvxkmmtkrb(spkugfwtgo) = cqgvufeybk spanzqftwk (cjnxjuckea )	Positive	01 Feb 2025
				Multiple daily insulin injections (MDI)	qvxkmmtkrb(spkugfwtgo) = udgiilffqg spanzqftwk (cjnxjuckea ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis